Immunopathology, Diagnosis and Treatment of HPV induced Malignancies

Dr. Prashant Khare is a Vice President (R&D) at Xenesis Institute, Absolute in Gurugram (Haryana), India. Previously, he was a Ramalingaswami Fellow and Scientist D in the Department of Microbiology at the All India Institute of Medical Sciences, Bhopal, India. He completed his PhD from the Division of Parasitology at the Central Drug Research Institute in Lucknow, (Uttar Pradesh), India. He has almost five years of postdoctoral experience from the Baylor Institute for Immunology Research and UT Southwestern Medical Center in Dallas, Texas, USA, and more than 15 years of research experience in the field of infectious biology, immunology, vaccine, and drug development. He has published more than 30 research papers in highly reputable international journals such as Nature Immunology and Nature Communication. He has reviewed publications and served in an editorial role for several international journals as well. Dr. Ashish Jain is Associate Professor in the Department of Microbiology, Smt. CHM College, Ulhasnagar, affiliated with the University of Mumbai (Maharashtra), India. He has completed his PhD from the Division of Endocrinology, CSIR-Central Drug Research Institute, Lucknow (Uttar Pradesh), India, on spermicides and sexually transmitted infections. He has published more than 50 reputed international research papers and reference books in the field of sexually transmitted infections, microbiology and reproductive biology and credited international patents in his account. He is a recognized postgraduate teacher and PhD guide at the University of Mumbai in the subject of microbiology. Presently, he is working to investigate the role of vaginal microbiota on reproductive health.

• 1. An overview of HPV: cause, symptoms and clinical manifestation2. Pathogenesis and immune response against HPV infection3. Malignancies associated with HPV infection4. Immunological aspects of HPV/HIV co-infection and risk of gynaecological diseases5. Cervico-vaginal microbiota and HPV induced cervical cancer6. Current diagnostic tools for HPV7. Animal models for the discovery of therapeutic and prophylactic measures against HPV induced malignancies8. Potential drug targets against HPV and repurposing of existing drugs9. Recent advances and strategies in vaccine development against HPV10. Available immunotherapies and future opportunities to prevent HPV-associated cancers